The magnitude of benefit from adding taxanes to anthracyclines in the adjuvant settings of breast cancer:discussion of large trials and meta-analyses  

作　　者：Osama H.Elzaafarany Atlal Abusanad 

机构地区：[1]Cancer Management and Research Department,Medical Research Institute-Alexandria University,Alexandria 21561,Egypt [2]Faculty of Medicine,King Abdulaziz University Hospital,Jeddah 21589,Saudi Arabia

出　　处：《Journal of Cancer Metastasis and Treatment》2018年第1期178-185,共8页癌症转移与治疗（英文版）

摘　　要：The taxanes family of chemotherapy,which includes paclitaxel and docetaxel,has been incorporated in the adjuvant breast cancer treatments since 1990s.Sequential and concurrent use of taxanes was investigated with anthracyclines in many adjuvant early breast cancer randomized clinical trials.Results from taxanes trials showed inconsistent benefits.However,several meta-analyses showed significant survival benefit of adding taxanes.In this review article,data were collected and summarized from eleven large randomized trials and three meta-analyses to show and discuss the magnitude of benefit of taxanes-anthracyclines combination compared to anthracyclines only adjuvant regimens in early breast cancer.This article aims at providing the oncologists with a well-organized,inclusive and updated evidence.

关 键 词：Breast cancer adjuvant chemotherapy TAXANES ANTHRACYCLINES 

分 类 号：R73[医药卫生—肿瘤]